Evaluating survival factors in patients with Extranodal NK/T-cell Lymphoma
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study
This study looks at what factors might affect how long people with Extranodal NK/T-cell Lymphoma live and how well they respond to treatment, using past patient data to help predict their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04554511 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess prognostic factors affecting overall survival and progression-free survival in patients diagnosed with Extranodal NK/T-cell Lymphoma (ENKTL). It utilizes a retrospective cohort design, analyzing anonymized patient data collected from January 1, 2000, to August 31, 2020. The study will establish a prognostic predictive nomogram to aid in predicting outcomes for ENKTL patients based on their clinical characteristics. Pathological reviews of initial diagnoses will be conducted by designated pathologists to ensure accuracy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been newly diagnosed with ENKTL during the specified time frame.
Not a fit: Patients without complete clinical information or those lost to follow-up immediately after treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a valuable tool for predicting patient outcomes and guiding treatment decisions for ENKTL.
How similar studies have performed: Other studies have shown success in using prognostic nomograms for various cancers, suggesting potential for this approach in ENKTL.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly diagnosed with ENKTL * Patients diagnosed between January 1, 2000 and August 31, 2020 * Patients older than 18 years Exclusion Criteria: * Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Hua Wang — Sun Yat-sen University
- Study coordinator: Hua Wang
- Email: wanghua@sysucc.org.cn
- Phone: +862087342462
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.